Hirosawa K, Tanaka T, Hisada K, Bunko H
Sakakibara Heart Institute, Tokyo.
Kaku Igaku. 1991 May;28(5):461-76.
Multi-center clinical trial of 123I-metaiodobenzylguanidine (123I-MIBG) was carried out to assess its utility as a scintigraphic imaging agent reflecting sympathetic neuronal function in cardiovascular field. Studies were performed on patients with heart diseases of three categories, myocardial infarction, angina pectoris and cardiomyopathy. Scintigraphic images, reflecting sympathetic neuronal function were obtained with 123I-MIBG from all of those categories of patients and the efficacy of the imaging was revealed in 781 (95.0%) out of 822 patients. In some patients abnormality was suggested in sympathetic neuronal function with 123I-MIBG imaging, in spite of normal findings with myocardial perfusion scintigraphy by 201TlCl. In all 981 patients studied with 123I-MIBG, there have been no severe adverse reactions, except complaints of burning on injection site of the agent or nausea, etc. from 4 patients. We conclude that 123I-MIBG imaging is one of the effective tools for diagnostic use reflecting topical sympathetic neuronal function in the heart, judging from its safety and efficacy.
开展了一项关于123I-间碘苄胍（123I-MIBG）的多中心临床试验，以评估其作为反映心血管领域交感神经功能的闪烁显像剂的效用。对三类心脏病患者进行了研究，即心肌梗死、心绞痛和心肌病患者。使用123I-MIBG从所有这些类别的患者中获取了反映交感神经功能的闪烁显像图像，822例患者中有781例（95.0%）显示该显像有效。在一些患者中，尽管用201TlCl进行心肌灌注显像结果正常，但123I-MIBG显像提示交感神经功能异常。在所有981例接受123I-MIBG研究的患者中，除了4例患者出现注射部位烧灼感或恶心等主诉外，未出现严重不良反应。从其安全性和有效性来看，我们得出结论，123I-MIBG显像是反映心脏局部交感神经功能的有效诊断工具之一。
